UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients

This publication has 29 references indexed in Scilit:

• Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
  Cancer Chemotherapy and Pharmacology, 2013
• Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms
  Cancer Science, 2011
• Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results
  Annals of Oncology, 2010
• UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
  British Journal of Cancer, 2010
• Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2009
• UGT1A1*28 Genotype Predicts Gastrointestinal Toxicity in Patients Treated With Intermediate-Dose Irinotecan
  Pharmacogenomics, 2009
• Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers
  Oncology, 2009
• UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
  World Journal of Gastroenterology, 2009
• Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer
  Annals of Oncology, 2008
• UGT1A1Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan
  Journal of Clinical Oncology, 2007